AWARD NUMBER:  CDMRPL-19-0-PR180876
PR180876

TITLE:  Novel malaria multi-epitope vaccine design

PRINCIPAL INVESTIGATOR:  Dr. Martha Sedegah

CONTRACTING ORGANIZATION:  Naval Medical Research Center (NMRC)
Silver Spring, MD 20910

REPORT DATE:  JUNE 2020

TYPE OF REPORT:  Annual Technical Report

PREPARED FOR:  U.S. Army Medical Research and Development Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Novel malaria multi-epitope vaccine design

Martha Sedegah & Kwadwo Asamoah Kusi

E-Mail: martha.sedegah.civ@mail.mil; akusi@noguchi.ug.edu.gh

Naval Medical Research Center
503 Robert Grant Avenue, Silver Spring, MD 20910

Noguchi Memorial Institute for Medical Research
University of Ghana, Legon, Accra, GHANA

U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

Malaria is a serious infectious disease threat to U.S. military personnel deployed in malaria endemic areas, and an efficacious vaccine is not yet available. To date, most vaccine candidates that have entered clinical trials, whether subunit or whole organism, have components derived from single parasite strains and have largely not been successful due to the strain-dependent features of the elicited immune response. We proposed to identify conserved immunodominant HLA A and B-restricted T cell epitopes from four leading Plasmodium falciparum candidate antigens and utilize a self-assembling protein nanoparticle (SAPN) technology to produce multi-antigen, multi-epitope subunit malaria vaccines. We have completed recruitment and blood sample collection from 300 study subjects. DNA from all 300 subjects have been purified and HLA typing of all subjects has been completed. Interferon- gamma/Granzyme B FLUOROSpot T cell assays with 15mer overlapping peptide stimulation of subject PBMCs is currently on-going, with analysis of samples from 245 subjects currently completed. Of the 212 passed assays103 HLA-typed subject samples yielded a positive response to at least one of the 31 peptide pools. Analysis of FLUOROSpot assay data for the remaining 55 subjects is ongoing. This report will also present assay data on subject HLA typing, parasite diversity analysis, blood film microscopy and ELISA to assess anti-CSP antibodies as an exposure proxy.
1. Introduction
The most advanced malaria subunit vaccine, RTS,S, shows modest antibody-mediated efficacy of up to 50% over one year in children from endemic areas [2, 3] and is currently being further evaluated in pilots in three African countries. It is also known to be more effective against parasite that are closely related to the vaccine strain [4]. Despite the significant impact that RTS,S could potentially have in people entering malaria-endemic regions, it currently does not meet the WHO and US military requirements for a malaria vaccine, which are achievement of at least 80% efficacy against multiple Plasmodium falciparum (Pf) strains for at least one year [5]. Radiation-attenuated sporozoites (RAS) induce 100% protection in humans, with protection mediated mainly by CD8+ T cell-killing of malaria-infected hepatocytes expressing human leukocyte antigen (HLA) Class I-restricted malaria antigen epitopes [6, 7]. Identification of protection-associated HLA-class 1 restricted epitopes with wide population coverage within selected antigenic targets will greatly aid the development of novel subunit, multi-epitope pre-erythrocytic vaccines with similar efficacy.

While Pf3D7-based subunit vaccines potentially protect against infection with the homologous 3D7 parasites to some degree, they have not been shown to be very effective against genetically divergent parasite haplotypes. Protective immune responses are most likely induced against a mix of strain-specific and strain-transcending epitopes within single or multiple antigens and a focus on strain-transcending epitopes, such as those that are conserved across different parasite strains, will yield broad protection. Our strategy is to identify HLA class I-restricted epitopes within selected malaria antigens, particularly those that are conserved among strains, in individuals in malaria-endemic regions and assemble these into a multi-epitope vaccine. We will focus on the HLA supertypes A*01, A*02, A*03, B*07 and B*44 as these are known to be very predominant within the global population [8]. We propose to utilize a self-assembling protein nanoparticle (SAPN) technology to produce multi-antigen, multi-epitope malaria vaccines based on conserved immunodominant peptide sequences from four leading Pf antigens (PfCSP, PfAMA1, PfCelTOS and PfTRAP). We will test the hypothesis that SAPNs that display conserved HLA-class 1 restricted T cell epitopes from multiple malaria antigens can elicit strain-transcending cellular responses in the liver and protect against pre-erythrocytic stage of Pf development and prevent blood stage infection and/or clinical disease. Our goal is to develop a clinically relevant novel multi-antigen, multi-epitope malaria vaccine that can induce broad protection against multiple malaria parasite strains in genetically diverse human populations.

2. Keywords
Malaria, Plasmodium falciparum, immunity, vaccine, multi-epitope, nanoparticles, Human leukocyte antigen (HLA), T cell, apical membrane antigen 1 (AMA1), Circumsporozoite protein (CSP),
thrombospondin related anonymous protein (TRAP), Cell traversal for ookinetes and sporozoites (CelTOS), conserved epitopes,

3. Accomplishments

a. What were the major goals of the project?

<table>
<thead>
<tr>
<th>Specific Aim 1: Prediction and identification of HLA A<em>01, A</em>02, A<em>03, B</em>07 and B*44 Pf epitopes from natural malaria infections</th>
<th>Timeline Months</th>
<th>Site 1 (Partnering PI)</th>
<th>Site 2 (Initiating PI)</th>
<th>Status</th>
<th>Completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Task 1: Regulatory approvals for recruitment of human subjects and use of animals.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtask 1: Submit documents for local IRB review (NMIMR).</td>
<td>1-3</td>
<td>Dr. Kusi</td>
<td>Dr. Sedegah</td>
<td>completed</td>
<td>June 2019</td>
</tr>
<tr>
<td>Subtask 2: Submit documents for local IACUC and ACURO review (NMRC)</td>
<td>1-4</td>
<td>Dr. Sedegah</td>
<td></td>
<td>completed</td>
<td>June 2019</td>
</tr>
<tr>
<td>Subtask 3: Submit IRB approval and necessary documents for HRPO review.</td>
<td>4-5</td>
<td>Dr. Kusi</td>
<td>Dr. Sedegah</td>
<td>completed</td>
<td>August 2019</td>
</tr>
</tbody>
</table>

| Major Task 2: Conduct of field studies (Ghana) | | | | | |
| Subtask 1: Undertake community entry procedures and recruit study subjects | 6 | Dr. Kusi | | | |
| Hold community durbar to explain purpose of study. | 6-7 | | | | |
| Recruit 300 study subjects and collect biological specimens. | | | | | |
| Subtask 2: Molecular determination of subject HLA supertypes and parasite genetic diversity | 8-12 | Dr. Amoah | | HLA typing completed, parasite genetic diversity analysis on-going; data on completed aspects is presented below | HLA typing completed in May 2020 |
| Subtask 3: FLUOROSpot assays using CSP, AMA1, TRAP and CelTOS 15mer overlapping peptide pools (NMIMR) | 8-12 | Dr. Kusi | Dr. Sedegah | Overlapping peptides from the four study antigens procured and pools prepared at NMRC. Pooled samples were shipped to NMIMR for FLUOROSpot assays, which are still on-going now. Laboratory and data analysis of first 245 samples completed, results presented below) | |
b. What was accomplished under these goals?
After scientific review and ethics approval by the NMIMR-IRB, the NMRC-IRB and the subsequent approval from the Human Research Protections Office (HRPO) of the US Army Medical Research and Development Command, we proceeded to have a community interaction to inform and educate the study community about the study objectives. We have since then successfully completed the recruitment of 300 study subjects and processed their blood samples at NMIMR. Biological specimen including PBMCs, packed cells and plasma samples have been archived. DNA from all 300 participants have been purified and high-resolution HLA typing for all 300 subjects has been completed. The data is currently being used for bioinformatic prediction of immunodominant peptides within the 4 test antigens and subsequent identification of conserved 9-10mer sequences for chemical synthesis. FLUOROSpot assays to determine the numbers of interferon-gamma (IFN-γ)- and granzyme B (grzB) -secreting cells per million PBMCs are on-going, with the significant majority completed. ELISA to assess anti-CSP antibody levels have been completed. Blood film microscopy and PCR for detection of blood parasites have been completed. Parasite diversity analysis and gene sequencing of the four antigens (AMA1, CSP, TRAP, CelTOS) has commenced and is expected to be completed in the next three months.

**FLUOROSpot assay results:** Each subject’s PBMCs were tested against 15mer overlapping peptide pools covering the entire sequences of four malaria vaccine candidate antigens; CSP (a total of 9 peptide pools), AMA1 (12 peptide pools), TRAP (6 peptide pools) and CelTOS (4 peptide pools). About $4 \times 10^5$ PBMCs were suspended in 100 µl complete medium and incubated in wells of FLUOROSpot plates with antigen-specific peptide pools. For each stimulant, data was averaged for duplicate wells and expressed as the spot forming cells (sfc) per million PBMCs. Two criteria were used to identify positive responders; a stimulation index of 2 for any stimulant relative to the same subject’s unstimulated PBMCs, and a sfc/million difference of 10 between stimulated and unstimulated PBMCs. Any subject that tested positive against one or more of all 31 peptide pools tested was designated as a positive responder.

Laboratory and data analysis for 245 of the 300 archived PBMC samples have been completed. Of the 245 subject samples, assays for 212 subjects (86.5%) passed or quality control check, which is subject PBMC positivity to the positive control (Con A or PHA). Of the 212 subjects with passed assays, 108 (representing 51% of subjects whose assays passed) made a positive response against at least one of the 31 peptide pools. Subject SAN117 had the highest number of responses to 16 different peptide pools, followed by SAN118 with responses to 15 different peptide pools.

Among the positive peptide pools, there were 155, 119, 37, and 38 positive responses against CSP, AMA1, TRAP, and CelTOS respectively. Thus, CSP was the most recognized of the four antigens, followed by AMA1. The Cp9 pool had the greatest number of subject responses, followed by Cp7 pool (Figure 1). There was however no response in all subjects to the 5th peptide pool of TRAP (TD5).

![Figure 1](image1.png)

*Figure 1. Total number of positive peptide pools from all passed assays. These are based on responses in 108 out of 212 subjects' assays that passed our QC and had at least one positive peptide pool response.*

Laboratory analysis of the remaining 55 PBMC samples has also been completed and analysis of the data is pending.
**HLA typing results:** Human DNA was extracted from packed blood cells from the 300 subjects using the Flexigene DNA extraction kit. DNA aliquots were sent to ProImmune Inc. (UK) for high resolution HLA class I A and B typing using sequence-specific genotyping procedures. Two hundred and ninety-one (291) of the 300 subjects were successfully typed and of this number, 23% expressed HLA A01 supertypes, 34% expressed HLA A02, 45% expressed HLA A03, 47% expressed HLA B07 and 23% expressed HLA B44 supertypes. Five (5) of the 108 subjects who made positive FLUOROSpot responses were amongst the 9 subjects with no HLA typing data available. Thus, 103 subjects had at least one positive peptide response and HLA typing data. A similar trend of HLA supertype expression was observed for these 103 subjects with at least one positive FLUOROSpot response, although proportions that were positive to these five HLA supertypes were slightly higher than that of the entire study population (Figure 2).

**Molecular detection and genotyping of *P. falciparum***: In order to identify subjects who have active *P. falciparum* infections, a nested PCR was used to amplify the *P. falciparum* 18s rRNA gene using DNA from the 300 subjects as templates. After the nest 2 reaction, an aliquot of amplified products was run in a 2% agarose gel with ethidium bromide and the gel visualized under a UV transilluminator. A representative gel is presented in Figure 3.

Of the 300 samples, 192 (64%) were positive for *P. falciparum*. The breakdown of parasite-positive subjects by month of sampling is presented in Figure 4. DNA from these parasite-positive samples were subsequently used to assess diversity in the *P. falciparum* merozoite surface protein 2 (msp2) gene by another nested PCR procedure with parasite family-specific primers. This was to determine whether the identified parasites belonged to either the IC/3D7 or the FC27 allelic parasite families. Positive controls used were DNA samples from the 3D7 and DD2 (FC27 family) parasite variants. Representative gels for the IC/3D7 (Figure 5) and FC27 (Figure 6) family parasites are presented below. Of the 192 PCR-positive subjects, 62 had parasites that belong to the IC/3D7 family, 51 had parasites that belong to the FC27
family and 52 had mixed infections with both IC/3D7 and FC27 family parasites. 24 parasite positive samples did not yield any msp2 allele types

Detection of blood parasites by microscopy and RDTs: Giemsa-stained slides from all 300 study subjects have been examined independently by two Microscopists for parasites. Fifty-three (53) of the 300 subjects (18%) had microscopic parasites, and a monthly breakdown of this is presented in Figure 4. Parasitemia ranged between 40 and 4,492 parasites per µl of blood, with highest levels of parasitemia occurring in December 2019. Presence of parasites in blood was also assessed using malaria-specific rapid diagnostic tests (RDTs). By this method, 16% of subjects were identified as carrying *P. falciparum* infections, and a monthly breakdown of these is presented in Figure 4. Thus, there was significant concordance of parasite positivity rates between microscopy and RDTs, but the PCR estimates were significantly higher, as expected.

Anti-CSP antibody ELISA results: We assessed the levels of anti-CSP antibodies in the 300 subject plasma samples as a proxy for exposure to malaria infectious mosquito bites. We first utilized a full-length recombinant CSP protein from the 3D7 parasite clone as the coating antigen for antibody measurement, but also used two different synthetic conserved peptides (24mer NANP repeat and 24mer NANPNVDP repeat) from the central conserved repeat region of the CSP antigen. The premise for the use of these conserved peptides for antibody measurement is that the full-length recombinant CSP antigen will have epitopes that are polymorphic. If a significant quantity of anti-CSP antibodies bind to polymorphic epitopes, the levels of antibodies measured with the recombinant antigen may not directly reflect transmission intensity but could be affected by the CSP variants of infecting parasites being very distant from the 3D7 clone CSP recombinant. The conserved peptides will however not differ between parasite variants, and antibodies against these conserved sequences will be consistent irrespective of the infecting parasite variants.

For the respective assays, ELISA plates were coated with each antigen and blocked with skimmed milk overnight. Plates were then incubated with diluted plasma samples from the 300 study subjects and bound antibodies detected using anti-human IgG conjugated to horseradish peroxidase. Plates were developed with TMB as substrate, color development stopped by the addition of sulphuric acid and the optical densities read at 450 nm. Optical density data was converted into titers using the standard pooled plasma from malaria-experienced persons which was run on each ELISA plate. Plasma from 16 malaria-naive persons were included on multiple ELISA plates as negative controls, and the mean antibody titer plus three times the standard deviation of these negative control samples was estimated as the cutoff for seropositivity for antibodies to the respective antigens.

Antibody titers were generally higher against the recombinant antigen as expected, and lowest against the NANP-NVDP repeat region (Figure 7). Further comparison of antibody levels across the different sampling months show a distribution that mirrors parasite prevalence, especially as measured by RDT and microscopy (Figure 8). This was especially true for (recombinant vs peptides).
The data suggest that the levels of antibodies against the three antigens are all useful as proxies for parasite prevalence, but CSP and the NANP repeat may be most suitable as appreciable levels of antibodies are made against these.

c. What opportunities for training and professional development has the project provided?

The project currently has one Postdoctoral Fellow and three Research Assistants in full salary employment. In addition, the project has a number of laboratory staff who support various aspects of the conduct of project-related work and are paid allowances on the project. At the inception of the study, five field assistants were trained in the process of obtaining informed consent and two technical persons were given orientation regarding the taking of blood samples at the study site and the subsequent processing and packaging of samples for transport. Two persons involved in field activity coordination and making of community announcements for subject recruitment were engaged. We also had a trained counsellor as a member of the field team, to provide counselling support to study subjects who required counselling because of either their direct or indirect participation as study subjects. In the laboratory, the study procedures have been used to provide training for up to five research interns who are undertaking a mandatory one-year national service after completing their BSc training in various fields in the biological sciences. There is also a plan to carve some minor projects related to this project for two additional undergraduate students in the coming year.

d. How were the results disseminated to communities of interest?

The study is on-going and there has not been an official presentation of study results to the community since the greater part of laboratory analysis still on-going. Summaries of study data, packaged in a non-technical format, will be shared with the community after the second sampling period and laboratory analysis are completed. The study team however has constant interaction with the community leaders and staff of the health facility in the study community with regards to some
general observations the study has so far picked up, for the purposes of encouraging health service uptake and promoting openness with the community leaders.

Furthermore, results of all screening tests have been shared with the study subjects involved and where necessary, we have directed study subjects who required medical attention to the community health center for medical assistance. For study subjects who had malaria parasites in their blood at screening, the study paid for their malaria treatment by the health center.

e. **What do you plan to do during the next reporting period to accomplish the goals?**

For the next one-year reporting period, we expect to achieve the following;

i. Complete current on-going pool-specific FLUOROSpot assays and analyze the complete data to identify positive peptide pools from the four antigens.

ii. Complete the bioinformatic analysis using HLA typing data and select 9-10mer predicted conserved epitopes that are present in positive peptide pools. Selected peptides will subsequently be chemically synthesized.

iii. Select up to 150 of the original 300 study subjects to collect additional blood samples in Ghana for further analysis in the USA. Selection of the 150 subjects will be based on their having at least one of the five HLA supertypes of interest in this study, a positive response to at least one antigen-specific peptide pool from the earlier FLUOROSpot assays using 15mer-peptide pools and seropositivity for anti-CSP antibodies, which is our marker of exposure to infectious mosquito bites.

iv. Isolate PBMCs from up to 150 subjects in Ghana and ship anonymized cryopreserved PBMC samples to the NMRC laboratories in USA for epitope identification.

v. Perform FLUOROSpot assays at NMRC using the predicted/selected and chemically synthesized 9-10mer peptides, to identify conserved immunodominant epitopes from the four antigens.

vi. Use identified conserved immunodominant peptides to design and produce the self-assembling nanoparticle-based multi-epitope vaccine candidates.

vii. Draft at least two manuscripts based on our accumulated data, and within the reporting period, get at least one of these manuscripts accepted and published in a peer-reviewed journal.

4. **Impact**

Nothing to report

5. **Changes/problems**

Nothing to report

6. **Products**

Nothing to report
7. Participants & other collaborating organizations

i. Individuals who have worked on the project

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Research Identifier (ORCID ID)</th>
<th>Nearest person month</th>
<th>Contribution to project</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Martha Sedegah</td>
<td>Initiating PI</td>
<td>0000-0001-6385-508X</td>
<td>5</td>
<td>Over-all PI, conceived and designed the experiments, analyzed data</td>
</tr>
<tr>
<td>Maria Belmonte</td>
<td>Research Assistant</td>
<td>0000-0002-4103-6611</td>
<td>6</td>
<td>Assisted in performance of Fluorospot assays in NMIMR; Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
<tr>
<td>Harini Ganeshan</td>
<td>Research Assistant</td>
<td>0000-0003-1572-4725</td>
<td>6</td>
<td>Assisted in performance of Fluorospot assays in NMIMR Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
<tr>
<td>Jun Huang</td>
<td>Research Assistant</td>
<td>0000-0001-8139-3499.</td>
<td>6</td>
<td>Assisted in performance of Fluorospot assays in NMIMR Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
<tr>
<td>Arnel Belmonte</td>
<td>Research Assistant</td>
<td>0000-0002-1738-6240</td>
<td>1</td>
<td>Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
<tr>
<td>Sandra Inoue</td>
<td>Research Assistant</td>
<td>0000-0001-5225-668X</td>
<td>1</td>
<td>Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
<tr>
<td>Rachel Velasco</td>
<td>Research Assistant</td>
<td>0000-0003-0356-252X</td>
<td>1</td>
<td>Prepared peptides and Analyzed data from Fluorospot assays</td>
</tr>
</tbody>
</table>

ii. Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

NO

iii. What other organizations were involved as partners?

Organization name: Walter Reed Army Institute of Research (WRAIR)

Location of Organization: 503 Robert Grant Avenue, Silver Spring, MD 20910

Partner’s contribution to the project: Collaboration (subaward) with Dr. Evelina Angov as stated in SOW in Major task 4 (year 2)

8. Special reporting requirements

This is a collaborative award, and as such, a duplicative report will be submitted by both the Initiating and Partnering PIs.
Updated quad charts will also be uploaded along with the technical report.

9. Appendices

None